Category: CDMO

The metabolic peptide wave has changed the rules of pharma manufacturing. GLP-1 based therapies and next-generation incretin programs have pushed peptide demand from “specialty” to “strategic.” Market forecasts reflect that momentum: the GLP-1 weight-loss drugs market alone is projected to...

For more than a decade, pharma and biotech companies have lived with an uncomfortable truth: their supply chains are efficient, but fragile. COVID-19, geopolitical tensions, export controls, and logistics disruptions exposed a harsh reality that overdependence on a limited set...

In the pharmaceutical world, scaling up drug substance (API) manufacturing is a critical bridge between scientific innovation and patient access.

The journey from discovering a promising molecule to making it available in the market as a life-saving therapy is long, complex, and expensive.

Not too long ago, Contract Development and Manufacturing Organizations (CDMOs) were viewed simply as “the builders”, facilities where pharmaceutical companies outsourced production to save time or reduce costs. Their value was measured in efficiency, compliance, and scale.

In today’s fast-evolving pharmaceutical landscape, speed, scalability, and specialization are critical to success. That’s where Contract Development and Manufacturing Organizations (CDMOs) come in. For pharma innovators, from startups to global giants, CDMOs offer a strategic pathway to bring therapies from lab to...